FOLH1 and prostate cancer: The first small-molecule inhibitors of PSMA, based on the Glu-urea-Lys motif (123I-MIP-1072 and 123I-MIP-1095), were introduced into the clinic in 2008 for prostate cancer imaging [113,114].